Redcare Pharmacy (DE:RDC)
XETRA:RDC
Top Page
Redcare Pharmacy
(XETRA:RDC)
Select Model
Select Model
Rating:48Neutral
Price Target:
€38.00
▼(-5.00% Downside)
Action:ReiteratedDate:04/09/26
The score is primarily held back by weak financial quality (ongoing losses and a sharp swing to negative free cash flow) and bearish technicals (price well below key moving averages with negative MACD). Strong revenue growth and an equity-supported balance sheet provide some offset, but valuation remains constrained by negative earnings and no indicated dividend yield.
Positive Factors
Revenue Growth & Scale
Multi-year revenue scaling demonstrates durable demand and successful market expansion across European online pharmacy channels. Growing scale supports absorption of fixed costs, improves supplier negotiating power, and funds platform and fulfillment investments that can materially improve unit economics over time.
Negative Factors
Ongoing Losses
Persistent negative EBIT and net income show the company has not yet translated scale into durable operating profits. Continued losses limit internal funding, raise the probability of additional financing needs, and increase execution risk for margin recovery if competitive or regulatory headwinds intensify.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Scale
Multi-year revenue scaling demonstrates durable demand and successful market expansion across European online pharmacy channels. Growing scale supports absorption of fixed costs, improves supplier negotiating power, and funds platform and fulfillment investments that can materially improve unit economics over time.
Read all positive factors
Redcare Pharmacy (RDC) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€816.55M
Dividend YieldN/A
Average Volume (3M)132.76K
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth26.68%
EPS Growth-41.83%
CountryDE
Employees1,827
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-1.44
Shares Outstanding20,578,390
10 Day Avg. Volume128,637
30 Day Avg. Volume132,758
Financial Highlights & Ratios
PEG Ratio1.97
Price to Book (P/B)2.85
Price to Sales (P/S)0.45
P/FCF Ratio-23.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€97.93Price Target Upside144.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.32
Revenue Forecast (FY)€3.34B
Redcare Pharmacy Business Overview & Revenue Model
Company Description
Redcare Pharmacy NV owns and operates online pharmacies in Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands. It provides prescription medications, over-the-counter medications, and pharmacy-related beauty and personal car...
How the Company Makes Money
Redcare Pharmacy primarily makes money by selling pharmacy and health-related products online. Its core revenue stream is product sales to end customers (B2C), which generally includes (1) prescription medications (where permitted and depending on...
Redcare Pharmacy Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
57
Neutral
Cash Flow
43
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.94B | 2.37B | 1.80B | 1.20B | 1.06B |
| Gross Profit | 593.70M | 545.78M | 440.38M | 331.79M | 266.53M |
| EBITDA | 45.60M | 28.03M | 50.94M | -30.64M | -37.41M |
| Net Income | -37.70M | -45.46M | -12.04M | -77.65M | -74.19M |
Balance Sheet | |||||
| Total Assets | 1.25B | 1.00B | 1.02B | 729.47M | 783.08M |
| Cash, Cash Equivalents and Short-Term Investments | 203.50M | 177.56M | 204.16M | 184.00M | 283.46M |
| Total Debt | 415.60M | 247.38M | 244.84M | 255.19M | 236.43M |
| Total Liabilities | 767.30M | 493.31M | 469.56M | 374.84M | 367.66M |
| Stockholders Equity | 459.20M | 483.98M | 522.19M | 354.63M | 415.41M |
Cash Flow | |||||
| Free Cash Flow | -56.30M | 13.38M | 23.23M | -82.64M | -31.52M |
| Operating Cash Flow | 23.00M | 22.13M | 61.46M | -29.11M | 11.63M |
| Investing Cash Flow | -151.40M | 8.38M | -59.96M | -138.01M | -84.30M |
| Financing Cash Flow | 124.10M | -17.94M | 15.05M | -13.52M | 229.59M |
Redcare Pharmacy Technical Analysis
Neutral
40.00
Price Trends
50.53
Negative
57.00
Negative
71.11
Negative
Market Momentum
-3.14
Negative
46.86
Neutral
83.24
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:RDC, the sentiment is Neutral. The current price of 40 is above the 20-day moving average (MA) of 36.31, below the 50-day MA of 50.53, and below the 200-day MA of 71.11, indicating a neutral trend. The MACD of -3.14 indicates Negative momentum. The RSI at 46.86 is Neutral, neither overbought nor oversold. The STOCH value of 83.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:RDC.
Redcare Pharmacy Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | €1.43B | 49.55 | 4.19% | 0.20% | 1.16% | -43.53% | |
60 Neutral | €15.25M | -39.63 | 3.75% | 3.46% | -23.48% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €1.45B | -66.87 | 4.98% | ― | -18.82% | -113.85% | |
48 Neutral | €816.55M | -34.72 | -7.76% | ― | 26.68% | -41.83% | |
42 Neutral | €128.66M | -3.18 | -391.55% | ― | -64.15% | -39.31% |
* General Sector Average
DE:RDC
Redcare Pharmacy
40.00
-87.30
-68.58%
DE:B8FK
Biofrontera
2.53
0.15
6.30%
DE:BIO
Biotest
41.40
-1.00
-2.36%
DE:COP
CompuGroup Medical
27.05
5.02
22.77%
DE:GME
Geratherm Medical
2.76
-0.30
-9.66%
DE:HPHA
Heidelberg Pharma AG
2.72
0.11
4.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.